BIRMINGHAM, Ala.–(BUSINESS WIRE)–ProAssurance Corporation (NYSE:PRA) will report results for the quarter ended March 31, 2024 after the close of normal New York Stock Exchange trading on Monday, May 6, 2024.
ProAssurance will conduct a conference call at 10:00 AM ET on Tuesday, May 7, 2024 to discuss the results and other items of interest to investors participating in the call. We invite US-based investors to participate by dialing either (833) 470-1428 (toll free) or (404) 975-4839. International investors are invited to participate using country-specific dial-in numbers that may be found using this link: https://www.netroadshow.com/events/global-numbers?confId=63389. The access code for all attendees is 923054.
Please use https://www.netroadshow.com/events/login?show=77ece0eb&confild=63389 if you would like to pre-register to receive unique call access details and avoid operator wait times.
The conference call will also be webcast at https://events.q4inc.com/attendee/483256153.
A telephone replay of the call will be available for at least 7 days after the call date. US-based investors may access the replay by dialing (866) 813-9403 (toll free) or (929) 458-6194, and international investors may dial +44 (204) 525-0658. The access code for all attendees is 547985. A replay will be available for at least one year after the call date at ProAssurance.com.
About ProAssurance
ProAssurance Corporation is an industry-leading specialty insurer with extensive expertise in healthcare professional liability, products liability for medical technology and life sciences, legal professional liability, and workers’ compensation insurance. ProAssurance Group is rated “A” (Excellent) by AM Best. ProAssurance and its operating subsidiaries carry a Financial Strength Rating of “A-” (Strong) from Fitch Ratings.
For the latest on ProAssurance and its industry-leading suite of products and services, cutting-edge risk management and practice enhancement programs, follow @ProAssurance on X (formerly Twitter) or LinkedIn. ProAssurance’s YouTube channel regularly presents thought provoking, insightful videos that communicate effective practice management, patient safety and risk management strategies.
Contacts
Dana Hendricks, EVP, Chief Financial Officer
800-282-6242 • 205-877-4462 • DanaHendricks@ProAssurance.com
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…
